We found that GBM cells treated with RT (2 Gy) and TMZ (50 μM), corresponding to the TMZ concentration range (5.15 – 51.5 μM) in the cerebrospinal fluid (CSF) of GBM patients [45], displayed an increase in MMP-2 secretion (Fig. 5A), invadopodia-mediated FITC-gelatin degradation (Fig. 5B) and invadopodia formation (Fig. 5D). The gene discussed is MMP2; the disease is glioblastoma.